The therapeutic effect of FTY720 on lupus nephritis in autoimmune MRL/lpr mice

被引：0
|
作者：
Sugahara, K [1 ]
Kataoka, H [1 ]
Ohtsuki, M [1 ]
Hoshino, Y [1 ]
Chiba, K [1 ]
机构：
[1] Mitsubishi Pharma Corp, Res Lab 3, Pharmaceut Res Unit, Div Res & Dev, Yokohama, Kanagawa, Japan
来源：
IMMUNOLOGY 2004: AUTOIMMUNITY, GENETIC AND DEGENERATIVE DISORDERS, MALIGNANCIES, AND TRANSPLANTATION | 2004年
关键词：
D O I：
暂无
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
Sphingosine 1-phosphate receptor agonist, FTY720 at oral doses of 0.03 to 1 mg/kg exhibited the prophylactic and therapeutic effect on lupus nephritis spontaneously developed in MRL/lpr mice. The therapeutical administration of FTY720 resulted in a decrease in the number of T cells, especially CD4(+) T cells, infiltrated into kidney as well as reduction of lymphocytes in blood. Moreover, the elevation of Th1 cytokine/chemokine mRNA expression was decreased in kidneys of FTY720-treated group. These results suggest that FTY720 decreases autoreactive Th1 cell infiltration into kidneys by reduction of circulating lymphocytes in blood, and thereby shows a marked therapeutic effect on progressing lupus nephritis of MRL/lpr mice.
引用
下载
收藏
页码：271 / 274
页数：4
相关论文
共 50 条
  • [41] Skin disease is prevented but nephritis is accelerated by multiple pregnancies in autoimmune MRL/LPR mice
    Koekeny, G.
    Godo, M.
    Nagy, E.
    Kardos, M.
    Kotsch, K.
    Casalis, P.
    Bodor, C.
    Rosivall, L.
    Volk, H-D
    Zenclussen, A. C.
    Hamar, P.
    LUPUS, 2007, 16 (07) : 465 - 477
  • [42] FTY720 prevention of autoimmune diabetes is dose and stage dependent
    Popovic, J
    Kover, KL
    Moore, WV
    PEDIATRIC RESEARCH, 2004, 55 (04) : 139A - 139A
  • [43] Activation of the STAT1 signalling pathway in lupus nephritis in MRL/lpr mice
    Dong, J.
    Wang, Q-X
    Zhou, C-Y
    Ma, X-F
    Zhang, Y-C
    LUPUS, 2007, 16 (02) : 101 - 109
  • [44] Tricostatin A inhibits mesangial cell activation and lupus nephritis in MRL/lpr mice.
    Reilly, CM
    Mishra, N
    Kammer, G
    Gilkeson, G
    ARTHRITIS AND RHEUMATISM, 2002, 46 (09): : S226 - S226
  • [45] Therapeutic effect of dihydroartemisinin on lupus-prone MRL/lpr mice and its mechanism of action
    Jiang, A'pei
    Pan, Jieli
    Jiang, Fusheng
    Li, Meiya
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2019, 12 (08): : 9839 - 9844
  • [46] Complement inhibition with Crry prevents development of lupus nephritis in MRL/lpr mice.
    Bao, LH
    Haas, M
    Rakstang, J
    Holers, VM
    Quigg, RJ
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 : 54A - 54A
  • [47] THE ROLE OF POSTTRANSCRIPTIONAL MODIFICATIONS OF ORNITHINE DECARBOXYLASE (ODC) IN THE PATHOGENESIS OF LUPUS NEPHRITIS IN MRL-LPR LPR MICE
    HSU, HC
    THOMAS, T
    SEIBOLD, JR
    THOMAS, TJ
    ARTHRITIS AND RHEUMATISM, 1992, 35 (09): : S155 - S155
  • [48] FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis (EAE). I. Effect of FTY720 and FTY720-phosphate on myelin proteolipid protein-induce EAE in SJL/J mice
    Kataoka, H.
    Sugahara, K.
    Shimano, K.
    Maeda, Y.
    Koyama, M.
    Fukunari, A.
    Chiba, K.
    JOURNAL OF NEUROIMMUNOLOGY, 2006, 178 : 161 - 161
  • [49] Recombinant chaperonin 10 suppresses cutaneous lupus and lupus nephritis in MRL-(Fas)lpr mice
    Kulkarni, Onkar P.
    Ryu, Mi
    Kantner, Claudia
    Sardy, Miklos
    Naylor, Dean
    Lambert, Daniel
    Brown, Richard
    Anders, Hans-Joachim
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 (04) : 1358 - 1367
  • [50] Expression of platelet-derived growth factor in lupus nephritis in MRL/MpJ-lpr/lpr mice
    Entani, C
    Izumino, K
    Takata, M
    Futamura, A
    Nakagawa, Y
    Inoue, H
    Iida, H
    NEPHRON, 1997, 77 (01) : 100 - 104
12345